All Drug Discovery articles – Page 17
-
NewsTargeting inflammation to treat atherosclerosis and MASH
A glycine-based compound developed at the University of Michigan, originally designed to treat severe fatty liver disease, has shown powerful effects in reducing atherosclerosis and vascular calcification in animal models.
-
NewsTargeting zombie cells: a new treatment for chronic back pain
McGill University researchers have found that two drugs can eliminate senescent “zombie cells” in spinal discs, offering a potential new treatment for chronic low back pain.
-
ArticleUsing knowledge graphs in drug discovery (Part 2): how they’re shaping scientific progress
In this second interview of the series, Andreas Kolleger, Head of GenAI Innovation at Neo4j, discusses how knowledge graphs and AI are transforming scientific discovery and improving life sciences workflows.
-
ArticleAI in drug discovery: faster, smarter, better
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
-
NewsNew drug combination shows potential to treat enteroviruses
Researchers in Norway have identified a promising oral drug combination that may stop the replication of enteroviruses, a group of viruses responsible for illnesses ranging from the common cold to type 1 diabetes.
-
ArticleBuilding better drugs: how 3D models are shaping pre-clinical development
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
-
NewsAdvanced test predicts ALK inhibitor success in lung cancer
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
-
ArticleNext-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
-
ArticleAI-powered imaging for faster lung disease treatment
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
-
ArticleUsing knowledge graphs in drug discovery (Part 1): how they link to large language models
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
-
ArticleLB-102: Redefining schizophrenia treatment in drug discovery
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
-
NewsKey PKD findings could accelerate development of new treatments
Rutgers researchers have discovered new insights into how polycystic kidney disease (PKD) progresses, which could lead to more targeted treatments. This breakthrough may help improve therapies for PKD patients in the future.
-
ArticleAdvanced drug development for neurodegenerative diseases with α-synuclein
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
-
WebinarCancer drug discovery breakthroughs: research that’s changing lives
Watch this roundtable with cancer experts on breakthroughs in targets, models and therapies transforming early-stage oncology discovery.
-
NewsNew leadership at ELRIG aims to expand collaboration across drug discovery
ELRIG, a UK-based scientific community driving innovation in drug discovery, has appointed biopharma leader Dr Del Trezise as its new Chair - signalling a bold new chapter for the organisation.
-
ArticleSpirulina’s role in shaping the future of preventative biologics
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we ...
-
WebinarAI-powered drug discovery: Accelerating the development of life-saving therapies
AI in drug discovery is no longer theoretical. It’s already speeding up target identification, improving predictions, and cutting waste. Learn how to apply it in your own discovery pipeline.
-
ArticleEarly evidence and emerging trends: How AI is shaping drug discovery and clinical development
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
-
ArticleGylden’s gold platform trains T cells to kill viruses
What if vaccines could train your immune system to eliminate infections at the source? Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity - providing a precise and durable defence against complex infectious diseases.
-
ArticleAdvancements in hit identification for membrane protein drug discovery
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.